^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Uveal Melanoma

    Related cancers:
    Apply
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • Imunace (teceleukin) • MB-101
    A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit (NCT06805825)
    Phase 1
    Novelty Nobility, Inc.
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    02/03/2025
    Primary completion :
    08/30/2027
    Completion :
    12/31/2027
    KIT
    |
    NN3201
    Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (CA224-094) (NCT04552223)
    Phase 2
    Jose Lutzky, MD
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    11/10/2020
    Primary completion :
    01/04/2024
    Completion :
    01/04/2026
    LAG3 • CTLA4
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma (NCT05628883)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    11/22/2022
    Primary completion :
    12/01/2025
    Completion :
    12/31/2026
    BRAF • IL2
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • TIDAL-01
    Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors (ACROPOLI) (NCT04802876)
    Phase 2
    SOLTI Breast Cancer Research Group
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/12/2021
    Primary completion :
    09/30/2025
    Completion :
    03/31/2027
    PD-1
    |
    PD-1 expression
    |
    Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)
    IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma (DAR-UM-2) (NCT05987332)
    Phase 2/3
    IDEAYA Biosciences
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    10/31/2023
    Primary completion :
    01/15/2027
    Completion :
    01/15/2028
    HLA-A
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • Yervoy (ipilimumab) • dacarbazine • darovasertib (IDE196)
    Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma (KEYNOTE-G05) (NCT06784648)
    Phase 1/2
    BioInvent International AB
    Recruiting
    Last update posted :
    01/20/2025
    Initiation :
    12/11/2024
    Primary completion :
    09/30/2028
    Completion :
    06/30/2031
    PD-1 • FCGR2A
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • BI-1607
    Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (NCT06070012)
    Phase 2
    Diwakar Davar
    Not yet recruiting
    Last update posted :
    01/06/2025
    Initiation :
    01/31/2025
    Primary completion :
    11/30/2026
    Completion :
    11/30/2029
    LAG3 • CTLA4
    |
    HLA-A*02:01
    |
    Kimmtrak (tebentafusp-tebn)
    A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (Keynote MK-3475-B66) (NCT03611868)
    Phase 1/2
    Ascentage Pharma Group Inc.
    Recruiting
    Last update posted :
    07/19/2024
    Initiation :
    08/29/2018
    Primary completion :
    12/30/2024
    Completion :
    03/30/2025
    PD-L1
    |
    ATM mutation • TP53 wild-type
    |
    Keytruda (pembrolizumab) • alrizomadlin (APG-115)
    Vorinostat in Treating Patients With Metastatic Melanoma of the Eye (NCT01587352)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    05/29/2012
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    GNAQ • BAP1 • GNA11
    |
    Zolinza (vorinostat)
    A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (NCT05415072)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    04/29/2024
    Initiation :
    07/04/2022
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    GNAQ
    |
    DYP688
    Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease (NCI-2018-01211) (NCT03025256)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/11/2024
    Initiation :
    05/02/2018
    Primary completion :
    12/30/2025
    Completion :
    12/30/2025
    BRAF • IL2
    |
    Opdivo (nivolumab)